We're starting by developing entactogens (meaning “enabling touching within”). These medicines are a novel type of therapeutic that can act as catalysts for exploring challenging feelings without the normally accompanying self-criticism. The resulting emotional openness and honesty has as potential to heal trauma and accelerate psychotherapy, decision-making, and psychological growth. The best known entactogen, 3,4-methylenedioxymethamphetamine (MDMA, Midomafetamine), is being studied for several indications, including PTSD, Anxiety Disorders, and Substance Use Disorders. MDMA-assisted psychotherapy for PTSD was awarded Breakthrough Therapy status by the FDA and recently showed impressive results in the first of two planned Phase III trials sponsored by MAPS.org.
While most psychedelic medicines have 'mind blowing' qualities and require expensive clinical monitoring, we are designing our lead molecules to be gentler and safer, which we believe will allow them to be used more flexibly and in more settings.
Our initial activity is dedicated to securing patents and evaluating candidate molecules. Evaluation includes in vitro functional measures of mechanisms and in vivo estimation of therapeutic potential. We maximize our productivity and impact by collaborating with select academic partners and contract research organizations.